CSE bulletin 2023-1016

The common shares of ME Therapeutics Holdings Inc. have been approved for listing on the Canadian Securities Exchange.

Listing and disclosure documents will be available on the CSE website on the trading date.

ME Therapeutics is an early-stage Vancouver-based biotechnology company involved in the discovery and development of novel immuno oncology therapeutics targeting immune suppression in cancer. The company's main focus is on overcoming the suppressive effects of an important class of immune cells called myeloid cells in order to enhance anti-tumour immunity.

Issuer:  ME Therapeutics Holdings

Security type:  common shares

Symbol:  METX

Number of securities issued and outstanding:  23,561,105

Number of securities reserved for issuance:  10,503,890

CSE sector:  diversified industries

Cusip No.:  552767 10 5

ISIN:  CA 552767 10 5 4

Board lot:  500

Trading currency:  Canadian dollar

Listing date:  Oct. 12, 2023

Other exchanges:  not applicable

Fiscal year-end:  Aug. 31

Transfer agent:  Odyssey Trust Company

The exchange is accepting market-maker applications for METX.